For too long, CVS Health has been weighed down by the low-margin, high-friction distraction of actually handing sick people medicine. So when the Woonsocket-based conglomerate announced its plan to split off its retail pharmacy locations into a separate company by 2028, I practically stood up and applauded my Bloomberg terminal. By shedding the physical drugstores to focus entirely on its Aetna insurance arm and Caremark pharmacy benefits manager, leadership is finally admitting what the street has known for years: treating patients is a legacy cost center.
It takes genuine visionary courage for a healthcare company to look at the concept of health, look at the concept of care, and decisively amputate both to save the administrative overhead. I had drinks at The Polo Bar last week with a private equity guy who specializes in distressed clinical assets, and he was weeping with joy. For a decade, we have watched a beautiful financial instrument—a perfectly calibrated machine for denying coverage and pocketing manufacturer rebates—be held back by the archaic requirement to staff buildings with doctorate-holding chemists who put pills into little orange bottles.
Think about the fundamental economics of dispensing a physical medication. It requires inventory. It requires commercial real estate. It requires refrigeration, logistics, and human beings standing on their feet for twelve hours a day dealing with the coughing public. It is a capital-intensive nightmare that actively punishes the company’s bottom line every time a patient successfully maintains their pulse.
We finally realized that the physical act of exchanging a validated prescription for a course of antibiotics was completely diluting our core competency, which is sending you a letter three weeks later explaining why you paid out of pocket.
Look at the pristine balance sheets of Aetna and Caremark. These are elegant, asset-light businesses. They do not have stained carpets. They do not sell expired seasonal candy or garden hoses. They sit in the glorious, frictionless ether between a sick person and their doctor, quietly siphoning a toll for merely existing. When you give someone a medical treatment, you incur a cost. When you just manage their pharmacy benefits, you print money.
Caremark, specifically, is a masterpiece of modern American capitalism. As a Pharmacy Benefit Manager, it dictates which drugs are covered, negotiates secret rebates with pharmaceutical manufacturers, and keeps the spread while telling the patient their copay went up. It is a pure-play abstraction layer. Why would a sophisticated health-management entity want to tether its valuation to whether a teenager can successfully summon an employee to unlock the deodorant cabinet in downtown Boston?
The friction of reality has always been the enemy of scale. I sat next to an Aetna actuary on a flight from Teterboro last month, and he looked utterly exhausted. He explained to me that every time a retail pharmacist actually manages to locate a generic asthma inhaler and hand it to a wheezing customer, the parent company loses fourteen basis points of potential margin. You buy an insurance provider to leverage national scale, not so some guy with a sinus infection can ask a cashier which aisle has the pseudoephedrine.
The market is rewarding this pivot because a pure middleman carries zero physical inventory, whereas a retail storefront occasionally has to listen to a senior citizen complain about their deductible, which is a catastrophic drag on our quarterly guidance.
What happens to the spun-off retail stores in 2028? Frankly, that is not our problem as investors. Let them float away on an ice floe of endless, three-foot-long receipt tape. They can rebrand as a bleak standalone destination for purchasing greeting cards and waiting in line for forty-five minutes behind one person trying to resolve a Medicare Part D discrepancy. Without the protective umbrella of Aetna’s cash flow, the standalone pharmacies will be forced to survive on their own merits—which means they will likely just pivot to selling exclusively locked razor blades and Halloween decorations in July.
Let me be clear: we need more of this structural honesty across the entire economy. I want an airline that spins off its airplanes to focus purely on selling co-branded credit cards. I want a restaurant group that eliminates food to concentrate on its loyalty app. The physical delivery of a product is an operational failure, and CVS is merely the first to boldly abandon it.
The new, pure CVS Health will be liberated. Just thousands of executives, actuaries, and algorithms working in perfect harmony in a gleaming tower, generating record profits by denying a prior authorization for a knee replacement. No messy bodily fluids. No angry customers at a drive-thru window. If you want medicine, go find a local chemist. If you want healthcare, you want a conglomerate that is legally structured to ensure you never actually receive any.